OncoMatch/Clinical Trials/NCT06649331
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Is NCT06649331 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for advanced breast cancer.
Treatment: SHR-A1811 · SHR-A1921 · SHR-A2009 · SHR-A2102 · Famitinib · Trastuzumab (or biosimilar) · 9MW2821 — This is a prospective, open-label, multicenter, phase II platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Biomarker criteria
Allowed: ESR1 expression
Participants with any hormone receptor (HR) status will be allowed on study
Allowed: PR (PGR) expression
Participants with any hormone receptor (HR) status will be allowed on study
Allowed: HER2 (ERBB2) expression
The most recent pathology results will be considered for enrollment according to local testing of ER, PR and HER2
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: antibody-drug conjugate
Previously received ADCs
Must have received: CDK4/6 inhibitor
Participants with HR-positive breast cancer must have received prior CDK4/6 inhibitor
Lab requirements
Blood counts
hb ≥90 g/l (no blood transfusion within 14 days); anc ≥1.5 x 10^9 / l; plt ≥75 x 10^9 / l
Kidney function
serum cr ≤1.5×uln, endogenous creatinine clearance > 50 ml/min (cockcroft-gault formula)
Liver function
tbil ≤1.5×uln; alt and ast ≤3×uln; if liver metastases were present, alt and ast≤ 5×uln
Cardiac function
lvef≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify